Please login to the form below

Not currently logged in
Email:
Password:

Michael Fleming joins biosimilars firm Coherus

He has experience at Elan, Genentech and GSK

Coherus Biosciences has named Michael Fleming as senior VP, commercial strategy.

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.

He joins Coherus as it begins to advance its pipeline of biosimilars towards commercialisation, a process that has already seen it sign an alliance with Baxter to develop a biosimilar version of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).

“Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance,” said Danny Lanfear, CEO of Coherus.

“He will play a key role in defining strategies that effectively maximise the commercial potential of our products.”

Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

His other experience includes senior commercial roles at GlaxoSmithKline, Genentech, Nuvelo, Agendia and Campbell Alliance.

1st May 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics